• Explore /
  • Poster
  • / Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.

Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.

Abstract Poster

Authors

null

Qing Zhou

Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China, Guangzhou, China

Qing Zhou , Lin Wu , Bo Jiang , Yingying Du , Buhai Wang , Xiaohua Hu , Yong He , Mingfang Zhao , Yu Yao , Jiuwei Cui , Xiaorong Dong , Haibo Zhang , Rui Ma , Huijuan Wang , Jian Zhang , Jinjing Xia , Yanni Zhang , John W. Hayslip , Andrew X. Zhu , Yi-Long Wu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04322006

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2570)

DOI

10.1200/JCO.2023.41.16_suppl.2570

Abstract #

2570

Poster Bd #

412

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Caicun Zhou

First Author: Ying Cheng

First Author: Joachim Aerts